Meta-analysis: Pegylated interferon α-2a achieves higher early virological responses than α-2b in chronic hepatitis C

Alimentary Pharmacology and Therapeutics

Volumn 37, Issue 11, 2013, Pages 1065-1073

  Romero Gomez M ^a   Planas, R ^a,b   Ampuero, J ^a   Sola R ^c   Garcia Samaniego J ^a,d   Diago, M ^e   Crespo, J ^f   Calleja, J L ^g   Turnes, J ^h  

^a HOSPITAL UNIVERSITARIO DE VALME   (Spain)

^b HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^c INST MUNIC D INVESTIGACIO MEDICA   (Spain)

^d HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^e HOSPITAL GENERAL UNIVERSITARIO DE VALENCIA   (Spain)

^f HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

^g HOSPITAL UNIVERSITARIO PUERTA DE HIERRO   (Spain)

^h HOSPITAL MONTECELO   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

PEGINTERFERON; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2A PLUS RIBAVIRIN; PEGINTERFERON ALPHA2B; PEGINTERFERON ALPHA2B PLUS RIBAVIRIN; RIBAVIRIN; TELAPREVIR;

ARTICLE; DRUG EFFICACY; EARLY VIROLOGICAL RESPONSE; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; MEDICAL PARAMETERS; META ANALYSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RAPID VIROLOGICAL RESPONSE; SERODIAGNOSIS; TREATMENT RESPONSE;

ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; POLYETHYLENE GLYCOLS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECOMBINANT PROTEINS; TIME FACTORS; TREATMENT OUTCOME; VIRAL LOAD;

EID: 84877608664     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/apt.12314     Document Type: Article

References (32)

1. Shimotohno K,. Hepatitis C virus and its pathogenesis. Semin Cancer Biol 2000; 10: 233-40.
2. Bruno R, Sacchi P, Ciappina V, et al,. Viral dynamics and pharmacokinetics of peginterferon alpha-2a and peginterferon alpha-2b in naive patients with chronic hepatitis c: a randomized, controlled study. Antivir Ther 2004; 9: 491-7.
3. Glue P, Fang JW, Rouzier-Panis R, et al,. Pegylated interferon-alpha2b: pharmacokinetics, pharmacodynamics, safety, and preliminary efficacy data. Hepatitis C Intervention Therapy Group. Clin Pharmacol Ther 2000; 68: 556-67.
4. Ghany MG, Strader DB, Thomas DL, Seeff LB,. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009; 49: 1335-74.
5. Marcellin P, Bourliere M, Pawlotsky JM, Ouzan D,. HCV non-responder patients: definition of non-response and treatment strategy. Gastroenterol Clin Biol 2007; 31: 4S13-9.
6. European Medicines Agency. Pegasys (peginterferon alpha-2a) -EPAR- Product Information. Available at: http://www.emea.europa.eu/ema/index.jsp?curl= pages/medicines/human/medicines/000395/human-med-000974.jsp&mid= WC0b01ac058001d124, 2011. Accessed January 17, 2013.
7. European Medicines Agency. PegIntron (peginterferon alpha-2b) -EPAR- Product Information. Available at: http://www.ema.europa.eu/ema/index.jsp? curl=pages/medicines/human/medicines/000280/smops/Positive/human-smop-000346. jsp&mid=WC0b01ac058001d127, 2012. Accessed January 17, 2013.
8. ®) in chronic hepatitis C patients after multiple dosing. Hepatology 2000; 32: 394A.
9. Ascione A, De Luca M, Tartaglione MT, et al,. Peginterferon alfa-2a plus ribavirin is more effective than peginterferon alfa-2b plus ribavirin for treating chronic hepatitis C virus infection. Gastroenterology 2010; 138: 116-22.
10. Berak H, Horban A, Wasilewski M, Stanczak J, Kolakowska-Rzadzka A,. Randomized, open label trial comparing efficacy and safety of pegylated interferon alfa 2A vs alfa 2B treatment of patients with chronic hepatitis C infected with non 2/3 genotypes-12 week virological response analysis. Hepatology 2005; 42: 1.
11. Di Bisceglie AM, Ghalib RH, Hamzeh FM, Rustgi VK,. Early virologic response after peginterferon alpha-2a plus ribavirin or peginterferon alpha-2b plus ribavirin treatment in patients with chronic hepatitis C. J Viral Hepat 2007; 14: 721-9.
12. Laguno M, Cifuentes C, Murillas J, et al,. Randomized trial comparing pegylated interferon alpha-2b versus pegylated interferon alpha-2a, both plus ribavirin, to treat chronic hepatitis C in human immunodeficiency virus patients. Hepatology 2009; 49: 22-31.
13. McHutchison JG, Lawitz EJ, Shiffman ML, et al,. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med 2009; 361: 580-93.
14. Rumi MG, Aghemo A, Prati GM, et al,. Randomized study of peginterferon-alpha2a plus ribavirin vs peginterferon-alpha2b plus ribavirin in chronic hepatitis C. Gastroenterology 2010; 138: 108-15.
15. Scotto G, Palumbo E, Fazio V, Cibelli DC, Saracino A, Angarano G,. Peginterferon alfa-2b treatment for patients affected by acute hepatitis C: presentation of six case reports. Infection 2005; 33: 30-2.
16. Silva M, Poo J, Wagner F, et al,. A randomised trial to compare the pharmacokinetic, pharmacodynamic, and antiviral effects of peginterferon alfa-2b and peginterferon alfa-2a in patients with chronic hepatitis C (COMPARE). J Hepatol 2006; 45: 204-13.
17. Yenice N, Mehtap O, Gumrah M, Arican N,. The efficacy of pegylated interferon alpha 2a or 2b plus ribavirin in chronic hepatitis C patients. Turk J Gastroenterol 2006; 17: 94-8.
18. Awad T, Thorlund K, Hauser G, Stimac D, Mabrouk M, Gluud C,. Peginterferon alpha-2a is associated with higher sustained virological response than peginterferon alfa-2b in chronic hepatitis C: systematic review of randomized trials. Hepatology 2010; 51: 1176-84.
19. Chen CH, Yu ML,. Evolution of interferon-based therapy for chronic hepatitis C. Hepat Res Treat 2010; 2010: 140953.
20. Jadad AR, Moore RA, Carroll D, et al,. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 1996; 17: 1-12.
21. DerSimonian R, Laird N,. Meta-analysis in clinical trials. Control Clin Trials 1986; 7: 177-88.
22. Higgins JP, Thompson SG,. Quantifying heterogeneity in a meta-analysis. Stat Med 2002; 21: 1539-58.
23. Marcellin P, Forns X, Goeser T, et al,. Telaprevir is effective given every 8 or 12 hours with ribavirin and peginterferon alfa-2a or -2b to patients with chronic hepatitis C. Gastroenterology 2011; 140: 459-68.
24. Scotto G, Fazio V, Fornabaio C, et al,. Peg-interferon alpha-2a versus Peg-interferon alpha-2b in nonresponders with HCV active chronic hepatitis: a pilot study. J Interferon Cytokine Res 2008; 28: 623-9.
25. Zeuzem S, Andreone P, Pol S, et al,. Telaprevir for retreatment of HCV infection. N Engl J Med 2011; 364: 2417-28.
26. Ghany MG, Nelson DR, Strader DB, Thomas DL, Seeff LB,. An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology 2011; 54: 1433-44.
27. Pawlotsky JM,. Treatment failure and resistance with direct-acting antiviral drugs against hepatitis C virus. Hepatology 2011; 53: 1742-51.
28. Alkhouri N, Zein NN,. Protease inhibitors: silver bullets for chronic hepatitis C infection? Cleve Clin J Med 2012; 79: 213-22.
29. Berenguer M,. Systematic review of the treatment of established recurrent hepatitis C with pegylated interferon in combination with ribavirin. J Hepatol 2008; 49: 274-87.
30. Tatsch FF, Sette H Jr, Vianna D,. Pharmacoeconomics applied to chronic hepatitis C. Braz J Infect Dis 2006; 10: 51-4.
31. Wong JB,. Hepatitis C: cost of illness and considerations for the economic evaluation of antiviral therapies. Pharmacoeconomics 2006; 24: 661-72.
32. Camma C, Petta S, Enea M, et al,. Cost-effectiveness of boceprevir or telaprevir for untreated patients with genotype 1 chronic hepatitis C. Hepatology 2012; 56: 850-60.